Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy

HIV Clinical Trials

Volumn 4, Issue 5, 2003, Pages 301-310

  Loutfy, Mona ^a   Raboud, Janet ^b,c   Thompson, Courtney ^c   Tseng, Alice ^c   Abdurrahman, Zainab ^d   Kovacs, Colin ^b,e   Rachlis, Anita ^b,f   Phillips, Elizabeth ^b,f   Rubin, Gary ^e   Gough, Kevin ^b,g   Walmsley, Sharon ^b,c,h  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF WATERLOO   (Canada)

^e Canadian Immunodeficiency Research Collaborative   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h NONE   (Canada)

Author keywords

Amprenavir; Lopinavir ritonavir; Salvage therapy

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANADA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; VIRUS INHIBITION;

ADULT; ANTI-HIV AGENTS; CARBAMATES; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; ONTARIO; PROPORTIONAL HAZARDS MODELS; PYRIMIDINONES; RETROSPECTIVE STUDIES; RITONAVIR; SALVAGE THERAPY; SULFONAMIDES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0142248379     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/7LYW-GQFF-WPRQ-K3QW     Document Type: Article

References (22)

1. Bartlett J, Demasi R, Quinn J, Moxham C, Rousseau F. Meta-analysis of efficacy of triple combination therapy in antiretroviral-naive HIV-1 infected adults. In: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections; January 2000; San Francisco, CA. Abstract I519.
2. Loutfy MR, Walmsley SL. Salvage therapy in HIV infection. Exprt Opin Pharmacother. 2002;3:81-90.
3. Smith GHR, Klein M, Leblanc R, MacCleod J, Routy JP, Lalonde R. Salvage therapy for HIV-1 infection with lopinavir/ritonavir (LOP/RIT), saquinavir-SGC (SQR), and nucleoside analogues in patients having failed all three antiretroviral classes. In: Proceedings of the 10th Canadian Conference on HIV/AIDS Research; May 2001; Toronto, Canada. Abstract I212.
4. Ruiz L, Ribera E, Bonjochl A, et al. Virological and immunological benefit of a salvage therapy that includes Kaletra plus Fortovase preceded or not by antiretroviral therapy interruption (TI) in advanced HIV-infected patients (6-month follow-up). In: Proceedings of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle, WA. Abstract 421-W.
5. Helliger J, Morris AB, Piscitelli S, et al. Pilot study of saquinavir-SGC (Fortovase, SQV) 1000 mg twice daily and lopinavir/ritonavir (Kaletra, LPV/r) in protease inhibitor-experienced HIV+ individuals: dose escalation and combined normalized inhibitory quotient (cNIQ). In: Proceedings of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle, WA. Abstract 421-W.
6. Staszewski S, Dauer B, Stephan C, Gute P, Klauke S, Sturmer M. Switch to a simple boosted double protease inhibitor regimen of lopinavir/r and saquinavir without reverse transcriptase inhibitors after multiple therapy failures. In: Proceedings of the XIV International AIDS Conference; July 2002; Barcelona, Spain. Abstract TuPeB4474.
7. Zala C, Patterson P, Coll P, et al. Virological response and safety at 48 weeks of double boosted protease inhibitors with Lopinavir/R plus either Saquinavir or Amprenavir in heavily pretreated HIV infected patients. In: Proceedings of the XIV International AIDS Conference; July 2002; Barcelona, Spain. Abstract TuPeB4492.
8. Khanlou H, Graham E, Brill M, Farthing C. Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy [letter]. AIDS. 2002;16:797-798.
9. Stein AJ, Brothers CH, Scott TR. Effect of reduced-dose amprenavir in combination with lopinavir on plasma levels of amprenavir in patients infected with HIV. Clin Ther. 2001;23:513-515.
10. Duval X, Race E, Lamotte C, et al. Inhibitory quotient and efficacy of amprenavir-lopinavir containing HAART in heavily pretreated HIV infected patients. In: Proceedings of the Second International Workshop on Clinical Pharmacology of HIV Therapy; April 2001; Noordwijk, The Netherlands. Abstract 5.11.
11. Peytavin G, Lamotte C, Duval X, et al. Amprenavir (APV) plasma concentrations are dramatically decreased by association with ABT378/r in HIV-infected patients. In: Proceedings of the Second International Workshop on Clinical Pharmacology of HIV Therapy; April 2001; Noordwijk, The Netherlands. Abstract 1.14.
12. Solas C, Quinson AM, Couprie C, et al. Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy. In: Proceedings of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle, WA. Abstract 440-W.
13. Baldini F, Rizzo MG, Hoetelmans R, et al. A prospective study of deep salvage therapy with lopinavir/r, amprenavir, and NRTIs: final 24-week data, pharmacokinetics, and association of drug levels/drug susceptibility with virologic response. In: Proceedings of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle, WA. Abstract 423-W.
14. Mauss S, Schmutz G, Kuschak D. Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir? AIDS. 2002;16:296-297.
15. Romer K, Fatkenheuer G, Kamps R, Salzberger B, Burger D. Pharmacokinetics of amprenavir and lopinavir in combination with ritonavir and nevirapine in highly pretreated HIV infected patients. In: Proceedings of the Eighth European Conference on Clinical Aspects and Treatment of HIV Infection; October 2001; Athens, Greece. Abstract P166.
16. Fatkenheuer G, Romer K, Kamps R, Salzberger B, Burger D. Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients. AIDS. 2001;15:2334-2335.
17. Hsu A, Bertz R, Ashbrenner E, et al. Interaction of ABT-378/ritonavir with protease inhibitors in healthy volunteers. In: Proceedings of the First International Workshop on Clinical Pharmacology of HIV Therapy; March 2000; Noordwijk, The Netherlands. Abstract 2.4.
18. Mauss S, Schmutz G, Kuschak D. Unfavourable interaction of lopinavir and amprenavir in combination with ritonavir. In: Proceedings of the Eighth European Conference on Clinical Aspects and Treatment of HIV Infection; October 2001; Athens, Greece. Abstract P170.
19. van Heeswijk RP, Hoetelmans RM, Harms R, et al. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1998;719:159-168.
20. Lamotte C, Duval X, Peytavin G, Farinotti R. Amprenavir (APV) plasma concentrations are dramatically increased by association to ritonavir (RTV) baby-doses in HIV infected patients: possible combination with efavirenz (EFV). In: Proceedings of the XIII International AIDS Conference; July 2000; Durban, South Africa. Abstract WePeB123.
21. Molla A, Mo H, Vasavanonda S, et al. In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob Agents Chemother. 2002;46:2249-2253.
22. Miller V, Staszewski S, Sabin C, et al. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. J Infect Dis. 1999;180:530-533.